EANS-News: Epigenomics AG / Epigenomics welcomes reimbursement of the Septin9 blood based colorectal cancer test by Swiss Life in France

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Marketing/molecular diagnostics

Berlin, Germany, and Seattle, WA, U.S.A. (euro adhoc) - Press release

Epigenomics welcomes reimbursement of the Septin9 blood based
colorectal cancer test by Swiss Life in France

Berlin, Germany, and Seattle, WA, U.S.A., July 05, 2012 - Epigenomics
AG (Frankfurt Prime Standard: ECX), the German-American cancer
molecular diagnostics company, announced today that Swiss Life,
France's third largest private health insurance company, with nearly
two million policyholders, will provide the Septin9 blood based test
for the early detection of colorectal cancer (CRC) as part of a
preventive health program. As the first French insurance company to
provide the Septin9 test, Swiss Life is offering up to 50%
reimbursement of this test at a cost of E 95. French Social Security
does not currently cover the Septin9 test. With this decision, Swiss
Life France is demonstrating its strong commitment to the improved
prevention of CRC for its policyholders. Furthermore, the decision
underpins its pioneering approach to disease prevention. Since 2005,
Swiss Life has offered its policyholders an optional preventive
health package, approved by a committee of medical experts, which is
integrated into Swiss Life's health insurance contracts.

Colorectal cancer remains the third leading cause of cancer-related
deaths in France. The disease is curable when detected at the early,
localized stage. Crucially, survival rates decrease rapidly once the
tumor has spread to vital organs and patients start showing symptoms.

Geert Nygaard, CEO of Epigenomics, said: "We are extremely pleased
about the positive reimbursement decision and endorsement of the
Septin9 blood based test for CRC detection by Swiss Life France. Our
version of the test, Epi proColon® 2.0 CE, has recently become
commercially available in France and we look forward to working with
healthcare pioneers like Swiss Life to increase compliance to CRC
screening in order to improve health outcomes. Furthermore, today's
decision clearly confirms our recently implemented commercialization
approach in Europe under which we are working closely with key
players in the healthcare system".

"Swiss Life has always paid close attention to medical innovations.
This commitment allows us to offer our policyholders access to
effective prevention for continuing wellbeing. With 17,000 deaths
annually in France and 17 million people eligible to be screened,
colorectal cancer is a major public health issue for which Swiss Life
has agreed reimbursement of this innovative test," commented Pierre
François, CEO of Swiss Life Prévoyance et Santé in France.

Epi proColon® 2.0 CE is the world's first CE-marked molecular
diagnostic test for the early detection of colorectal cancer in
blood. The test uses Epigenomics' proprietary colorectal cancer
biomarker Septin9 in blood plasma and has recently become
commercially available in France.

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English